{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:00:22Z","timestamp":1790146822833,"version":"4.0.1"},"reference-count":143,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"DOI":"10.1080\/14656566.2026.2734125","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:22:32Z","timestamp":1789536152000},"page":"1-14","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Current and new approaches to the treatment landscape for adults with Waldenstr\u00f6m macroglobulinemia"],"prefix":"10.1080","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2601-0667","authenticated-orcid":false,"given":"Camille V.","family":"Edwards","sequence":"first","affiliation":[{"name":"Bing Center for Waldenstr\u00f6m\u2019s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA"},{"name":"Department of Medicine, Harvard School of Medicine, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9490-7532","authenticated-orcid":false,"given":"Jorge J.","family":"Castillo","sequence":"additional","affiliation":[{"name":"Bing Center for Waldenstr\u00f6m\u2019s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA"},{"name":"Department of Medicine, Harvard School of Medicine, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1190-5978","authenticated-orcid":false,"given":"Tarek H.","family":"Mouhieddine","sequence":"additional","affiliation":[{"name":"Bing Center for Waldenstr\u00f6m\u2019s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA"},{"name":"Department of Medicine, Harvard School of Medicine, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0075-6735","authenticated-orcid":false,"given":"Shayna R.","family":"Sarosiek","sequence":"additional","affiliation":[{"name":"Bing Center for Waldenstr\u00f6m\u2019s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA"},{"name":"Department of Medicine, Harvard School of Medicine, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015851"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50069"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.1.214"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2355079"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.668"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-384768"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.147"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17691"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50038"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00394"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0431-y"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02066"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-174961"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2002.n.022"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi022"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190410001714043"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.10.9926"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-647420"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00916-5"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15148"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26210"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27524"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3311-z"},{"key":"e_1_3_4_28_1","doi-asserted-by":"crossref","unstructured":"Rummel MJ Lerchenm\u00fcller C Hensel M et al. Two years rituximab maintenance vs. Observation after first line treatment with Bendamustine plus rituximab (B-R) in patients with Waldenstr\u00f6m\u2019s macroglobulinemia (MW): results of a prospective randomized multicenter phase 3 study (the StiL NHL7-2008 maintain trial) [abstract]. Blood. 2019;134(Supplement 1):343\u2013343.","DOI":"10.1182\/blood-2019-121909"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501548"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00555"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.6426"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01417-9"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24366"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25023"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001160"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006844"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18643"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02830"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010906"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199276"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00838"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802917"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025017713"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30210-8"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181500"},{"key":"e_1_3_4_46_1","doi-asserted-by":"crossref","unstructured":"Owen R McCarthy H Rule S et al. P1130: ACALABRUTINIB in TREATMENT-NAIVE or RELAPSED\/REFRACTORY WALDENSTR\u00d6M macroglobulinemia: 5-year FOLLOW-UP of a phase 2 SINGLE-ARM study [abstract]. Hemasphere. 2022;6:1020\u20131021. doi: 10.1097\/01.HS9.0000847388.33116.c7","DOI":"10.1097\/01.HS9.0000847388.33116.c7"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101682"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14561"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15344"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-879593"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.20016"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21788"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.4677"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.1833.1833"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01805"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-503862"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00649"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2005.071175"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-566273"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26641"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2023.03.002"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.7566"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090675"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1110748"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.289"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr119"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29334"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy458"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26895"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2023.04.004"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010324"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-475111"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200710"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02314"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3702"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.187"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-564583"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13897"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2019.1649132"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-026-02877-7"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15718"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25730"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-224"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13883"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.133744"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27759"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017794"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15049"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17050907"},{"key":"e_1_3_4_90_1","doi-asserted-by":"crossref","unstructured":"Berendsen MR Van Bladel DAG Hesius E et al. Clonal relationship and mutation analysis in lymphoplasmacytic lymphoma\/Waldenstr\u00f6m macroglobulinemia associated with diffuse large B-cell lymphoma. Hemasphere. 2023;7(11):e976. doi: 10.1097\/HS9.0000000000000976","DOI":"10.1097\/HS9.0000000000000976"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.07.014"},{"key":"e_1_3_4_92_1","unstructured":"NCCN clinical practice guidelines in oncology: B\u2011cell lymphomas (version 4). 2026 May 20."},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(25)00327-8"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-206415"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000115"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-811752"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16463"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761726"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00224-5"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-226"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13278"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01194"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-198728"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01271-3"},{"key":"e_1_3_4_107_1","volume-title":"Poster session presented at: European Hematology Association 2026 Congress","author":"Castillo JJ","year":"2026","unstructured":"Castillo JJ, Thomas SK, Palomba ML, et al. Patterns of treatment utilization and sequencing across lines of therapy in Waldenstrom macroglobulinemia (WM): real-world evidence from the United States. In: Poster session presented at: European Hematology Association 2026 Congress; Stockholm, Sweden; 2026 Jun 11\u201314."},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.70269"},{"key":"e_1_3_4_109_1","unstructured":"Cheah CY Tam CS Garcia-Sanz R et al. Updated safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) for relapsed\/refractory Waldenstrom macroglobulinemia. HemaSphere. 2025;9(S1):e70152."},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26796"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13264"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001963"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016536"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)02192-X"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-185113"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022420"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-225"},{"issue":"1","key":"e_1_3_4_118_1","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1182\/blood-2024-200604","article-title":"Bortezomib in combination with ibrutinib\/rituximab is a highly effective and well tolerated first - line treatment for Waldenstr\u00f6m\u2019s macroglobulinemia: results of the multicenter phase ii trial (ECWM-2) of the European consortium for Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"144","author":"Buske C","year":"2024","unstructured":"Buske C, Kastritis E, Grunenberg A, et al. Bortezomib in combination with ibrutinib\/rituximab is a highly effective and well tolerated first - line treatment for Waldenstr\u00f6m\u2019s macroglobulinemia: results of the multicenter phase ii trial (ECWM-2) of the European consortium for Waldenstr\u00f6m\u2019s macroglobulinemia [abstract]. Blood. 2024;144(Supplement 1):859\u2013859.","journal-title":"Blood"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-198864"},{"key":"e_1_3_4_120_1","first-page":"16","volume-title":"The 12th International Workshop on Waldenstr\u00f6m Macroglobulinemia (IWWM-12)","volume":"10","author":"Dimopoulos M","year":"2024","unstructured":"Dimopoulos M, Gavriatopoulou M, Kastritis E. Carflizomib with and without ibrutinib in frontline and relapsed\/refractory WM (CZAR01). In: The 12th International Workshop on Waldenstr\u00f6m Macroglobulinemia (IWWM-12); Prague, CZ; 2024. Vol. 10. p. 16\u201319."},{"key":"e_1_3_4_121_1","first-page":"16","volume-title":"The 12th International Workshop on Waldenstr\u00f6m Macroglobulinemia (IWWM-12)","volume":"10","author":"Berinstein N","year":"2024","unstructured":"Berinstein N. A phase ii trial of Bendamustine, rituximab and acalabrutinib in previously untreated Waldenstr\u00f6m\u2019s macroglobulinemia (BRAWM). In: The 12th International Workshop on Waldenstr\u00f6m Macroglobulinemia (IWWM-12); Prague, CZ; 2024. Vol. 10. p. 16\u201319."},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-198882"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02317-4"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.adi5798"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199212"},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-3583"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-5359"},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00139-X"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-211573"},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-581"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011994"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8034"},{"issue":"1","key":"e_1_3_4_133_1","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2024-199182","article-title":"Reducing time toxicity for Anti-B-Cell maturation antigen (BCMA) bispecific treatment: evidence from pivotal single-arm trial data on teclistamab, Elranatamab, and linvoseltamab for triple-class exposed (TCE) relapsed\/refractory multiple myeloma (RRMM) [abstract]","volume":"144","author":"Ailawadhi S","year":"2024","unstructured":"Ailawadhi S, Inocencio TJ, Zhou Z-Y, et al. Reducing time toxicity for Anti-B-Cell maturation antigen (BCMA) bispecific treatment: evidence from pivotal single-arm trial data on teclistamab, Elranatamab, and linvoseltamab for triple-class exposed (TCE) relapsed\/refractory multiple myeloma (RRMM) [abstract]. Blood. 2024;144(Supplement 1):2271\u20132271.","journal-title":"Blood"},{"key":"e_1_3_4_134_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01254-4"},{"key":"e_1_3_4_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2026.04.023"},{"key":"e_1_3_4_136_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025130"},{"key":"e_1_3_4_137_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023419"},{"key":"e_1_3_4_138_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010064"},{"key":"e_1_3_4_139_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.287215"},{"key":"e_1_3_4_140_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024452"},{"key":"e_1_3_4_141_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004128"},{"key":"e_1_3_4_142_1","doi-asserted-by":"crossref","unstructured":"Shadman M Yeung C Redman MW et al. P1097: CD20 CAR-T therapy with MB-106 for BTK INHIBITOR-REFRACTORY WALDENSTR\u00d6M macroglobulinemia (WM)\/ LYMPHOPLASMACYTIC lymphoma (LPL) \u2013 single institution study [abstract]. Hemasphere. 2023;7(S3):e68877ca. doi: 10.1097\/01.HS9.0000971284.68877.ca","DOI":"10.1097\/01.HS9.0000971284.68877.ca"},{"key":"e_1_3_4_143_1","doi-asserted-by":"publisher","DOI":"10.1080\/13548506.2021.1913756"},{"key":"e_1_3_4_144_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2699"},{"key":"e_1_3_4_145_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-519"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2734125","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14656566.2026.2734125","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2734125","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:07:29Z","timestamp":1790143649000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2026.2734125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":143,"alternative-id":["10.1080\/14656566.2026.2734125"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2026.2734125","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-07-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}